Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma
NCT02724579Phase 2Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Nov 2017
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 5
01
Overview
A Phase 2 trial of Cisplatin micelle injection (HA132), cyclophosphamide, lomustine, vincristine sulfate liposome injection in medulloblastoma, sponsored by Children's Oncology Group. Started Nov 2017; status: active, not recruiting.
02
Drugs
Cisplatin micelle injection (HA132)cyclophosphamidelomustinevincristine sulfate liposome injection
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT02724579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02724579.